Robbie Marcus
Stock Analyst at JP Morgan
(4.27)
# 480
Out of 4,761 analysts
154
Total ratings
60.78%
Success rate
12.45%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNMD CONMED | Downgrades: Neutral | $85 → $70 | $61.14 | +14.50% | 6 | Feb 6, 2025 | |
| SYK Stryker | Maintains: Overweight | $420 → $445 | $386.23 | +15.22% | 9 | Jan 29, 2025 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $575 → $675 | $604.10 | +11.74% | 5 | Jan 24, 2025 | |
| NPCE NeuroPace | Maintains: Overweight | $9 → $14 | $13.88 | +0.86% | 4 | Dec 17, 2024 | |
| BVS Bioventus | Upgrades: Neutral | $12 → $13 | $9.93 | +30.98% | 3 | Dec 17, 2024 | |
| ZBH Zimmer Biomet Holdings | Upgrades: Overweight | $125 → $128 | $104.50 | +22.49% | 5 | Dec 17, 2024 | |
| BSX Boston Scientific | Maintains: Overweight | $100 → $110 | $105.32 | +4.44% | 13 | Dec 16, 2024 | |
| PODD Insulet | Maintains: Overweight | $280 → $330 | $283.54 | +16.39% | 4 | Dec 12, 2024 | |
| CBLL CeriBell | Initiates: Overweight | $32 | $23.72 | +34.91% | 1 | Nov 5, 2024 | |
| ATRC AtriCure | Maintains: Overweight | $30 → $40 | $39.46 | +1.37% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $78 | $73.91 | +5.53% | 4 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $85 | $88.66 | -4.12% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $91.07 | -1.17% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $44.03 | +13.56% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $44 → $42 | $33.61 | +24.96% | 16 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $5.73 | - | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $9.67 | -17.27% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $36 → $13 | $14.04 | -7.37% | 5 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $100 → $120 | $88.44 | +35.69% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $62 | $30.23 | +105.09% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $301.40 | -17.05% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $16 | $13.27 | +20.57% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $10.30 | -32.04% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $340 → $181 | $176.84 | +2.36% | 4 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $56 → $43 | $22.11 | +94.48% | 5 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $15.96 | +6.55% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $134.39 | -12.19% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $121.00 | +28.93% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $130 → $105 | $89.67 | +17.10% | 11 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $139.45 | -71.32% | 2 | May 5, 2020 |
CONMED
Feb 6, 2025
Downgrades: Neutral
Price Target: $85 → $70
Current: $61.14
Upside: +14.50%
Stryker
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $386.23
Upside: +15.22%
Intuitive Surgical
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $604.10
Upside: +11.74%
NeuroPace
Dec 17, 2024
Maintains: Overweight
Price Target: $9 → $14
Current: $13.88
Upside: +0.86%
Bioventus
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $9.93
Upside: +30.98%
Zimmer Biomet Holdings
Dec 17, 2024
Upgrades: Overweight
Price Target: $125 → $128
Current: $104.50
Upside: +22.49%
Boston Scientific
Dec 16, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $105.32
Upside: +4.44%
Insulet
Dec 12, 2024
Maintains: Overweight
Price Target: $280 → $330
Current: $283.54
Upside: +16.39%
CeriBell
Nov 5, 2024
Initiates: Overweight
Price Target: $32
Current: $23.72
Upside: +34.91%
AtriCure
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $39.46
Upside: +1.37%
Oct 25, 2024
Maintains: Neutral
Price Target: $72 → $78
Current: $73.91
Upside: +5.53%
Oct 25, 2024
Maintains: Neutral
Price Target: $75 → $85
Current: $88.66
Upside: -4.12%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $91.07
Upside: -1.17%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $44.03
Upside: +13.56%
Aug 7, 2024
Maintains: Neutral
Price Target: $44 → $42
Current: $33.61
Upside: +24.96%
Aug 7, 2024
Downgrades: Underweight
Price Target: n/a
Current: $5.73
Upside: -
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $9.67
Upside: -17.27%
May 1, 2024
Downgrades: Neutral
Price Target: $36 → $13
Current: $14.04
Upside: -7.37%
Mar 13, 2024
Upgrades: Overweight
Price Target: $100 → $120
Current: $88.44
Upside: +35.69%
Feb 29, 2024
Maintains: Overweight
Price Target: $40 → $62
Current: $30.23
Upside: +105.09%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $301.40
Upside: -17.05%
Dec 20, 2023
Maintains: Neutral
Price Target: $10 → $16
Current: $13.27
Upside: +20.57%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $10.30
Upside: -32.04%
Oct 17, 2023
Maintains: Overweight
Price Target: $340 → $181
Current: $176.84
Upside: +2.36%
May 24, 2023
Downgrades: Underweight
Price Target: $56 → $43
Current: $22.11
Upside: +94.48%
Feb 23, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $15.96
Upside: +6.55%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $134.39
Upside: -12.19%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $121.00
Upside: +28.93%
Dec 17, 2021
Downgrades: Neutral
Price Target: $130 → $105
Current: $89.67
Upside: +17.10%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $139.45
Upside: -71.32%